Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025
Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Company

Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move

Fineline Cube Jun 18, 2025

Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...

Company Deals

Novo Nordisk Partners with Alibaba Health to Launch Weight Management Hub”

Fineline Cube Jun 18, 2025

Denmark-based Novo Nordisk (NYSE: NVO) has entered into a partnership with China’s Alibaba Health Information...

Company

Legend Biotech Plans to Disband China Sales Team Amid Carvykti Commercialization Challenges

Fineline Cube Jun 18, 2025

Reports indicate that China-based Legend Biotech Corporation (NASDAQ: LEGN) plans to disband its China sales...

Company Deals

Pierre Fabre Acquires Global Rights to EGFR Inhibitors PFL-721 and PFL-241 from Antares Therapeutics

Fineline Cube Jun 17, 2025

France-based Pierre Fabre Laboratories announced the acquisition of global rights to PFL-721 and PFL-241 from...

Company Deals

Hasten Biopharmaceutical Accelerates Asia-Pacific Expansion With 11 MAT Transfers

Fineline Cube Jun 17, 2025

China-based Hasten Biopharmaceutical Co., Ltd, backed by CBC Group, announced the completion of Market Authorization...

Company Drug

Sino Biopharmaceutical’s TDI01 Receives Breakthrough Therapy Designation for cGVHD Treatment

Fineline Cube Jun 17, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Class 1 drug TDI01 has been...

Company Deals Medical Device

3D Medicines Partners with MGI Tech for Precision Medicine Solutions in Oncology and Infectious Diseases

Fineline Cube Jun 17, 2025

China-based 3D Medicines (HKG: 1244) announced a strategic collaboration with domestic gene sequencing specialist MGI...

Company Deals

Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia

Fineline Cube Jun 17, 2025

China’s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical...

Company Deals

BioMérieux Set to Acquire Day Zero Diagnostics to Boost Infectious Disease R&D Pipeline

Fineline Cube Jun 17, 2025

France-based BioMérieux is set to acquire the assets of Day Zero Diagnostics, a US-based infectious...

Company Drug

Suzhou GenAssist’s GEN6050X Gains FDA Orphan Drug Status for Duchenne Muscular Dystrophy

Fineline Cube Jun 17, 2025

China-based Suzhou GenAssist Therapeutic Co., Ltd. announced that its in vivo base editing therapy, GEN6050X,...

Company Deals

BioTroy Therapeutics Secures USD 28M in Series A Funding for CD3L1 Anti-Tumor Drug Development

Fineline Cube Jun 17, 2025

Shanghai-based BioTroy Therapeutics, a cancer immunotherapy developer, has reportedly secured over RMB 200 million (USD...

Company Deals

GlycoT Therapeutics Partners with Innovent Biologics to Advance ADC Technology

Fineline Cube Jun 17, 2025

US-based GlycoT Therapeutics LLC last week inked a license agreement with Innovent Biologics, Inc. (HKG:...

Company Deals

Shanghai Escugen and SunRock Biopharma Collaborate on First-in-Class CCR9-Targeted ADC

Fineline Cube Jun 17, 2025

China-based Shanghai Escugen has partnered with Spain-headquartered SunRock Biopharma, S.L. to co – develop SRB123,...

Company Drug

AbbVie’s Venclexta Fails to Meet Overall Survival Endpoint in HR-MDS Trial

Fineline Cube Jun 17, 2025

US-based major AbbVie Inc., (NYSE: ABBV) has revealed disappointing data for its Venclexta (venetoclax) in...

Company Legal / IP

Harbour BioMed Wins CNIPA Validation of ‘Binding Molecule’ Patent Amid Dispute

Fineline Cube Jun 17, 2025

China-based Harbour BioMed (HKG: 2142) announced that the China National Intellectual Property Administration (CNIPA) has...

Company Drug

Roche Advances Prasinezumab to Phase III for Early Parkinson’s Disease

Fineline Cube Jun 17, 2025

Switzerland-based Roche (SWX: ROG, OTCMKTS: RHHBY) announced its decision to advance prasinezumab, an anti-α-synuclein antibody...

Company Deals

Simcere and NextCure Forge Strategic Alliance to Co-Develop SIM0505 ADC for Solid Tumors

Fineline Cube Jun 17, 2025

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming and US-headquartered NextCure, Inc. (NASDAQ:...

Company

AstraZeneca’s Oncology Executive Michael Lai to Leave Company in June

Fineline Cube Jun 17, 2025

Lai Minglong (Michael Lai), head of AstraZeneca’s (AZ, NASDAQ: AZN) global oncology business Dato-DXd and...

Company Deals

Eli Lilly Close to Acquiring Verve Therapeutics for Up to USD 1.3 Billion

Fineline Cube Jun 17, 2025

US-based pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) is reportedly in advanced negotiations to...

Company Drug

Pediatrix Therapeutics Wins Macau Approval for Neffy Epinephrine Nasal Spray

Fineline Cube Jun 17, 2025

China-based Pediatrix Therapeutics announced that it has received marketing approval in Macau for its neffy...

Posts pagination

1 … 78 79 80 … 602

Recent updates

  • Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial
  • HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology
  • Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics
  • AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
  • AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s TQH3906 Achieves 90% PASI 75 Response in Phase 2 Psoriasis Trial

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.